Bo Zhang, Runbo Zhong, Chunlei Shi, Tianqing Chu, Wei Zhang, Huimin Wang, Xin Gan, Zhihong Zhang, Changbin Zhu, Xing Li, Wenzhong Su, Juan Li, Yanwei Zhang, Baohui Han, Hua Zhong. "Durvalumab plus anlotinib versus durvalumab alone as maintenance treatment in extensive-stage small-cell lung cancer (DURABLE): a multicenter, randomized, phase II trial and biomarker analysis." Nature Communications, 2026. doi:10.1038/s41467-026-73562-7